Literature DB >> 6180097

Autoantibodies against human beta interferon following treatment with interferon.

A Vallbracht, J Treuner, K H Manncke, D Niethammer.   

Abstract

Recently we reported the appearance of human beta interferon (HuIFN-beta) neutralizing antibodies in a patient with a nasopharyngeal carcinoma treated successfully with a preparation of HuIFN-beta. This was the first report presenting evidence for antigenicity of IFN in an homologous system. In the present report we asked whether the unusual appearance of antibodies was due to a genetic defect of the patient's cells to produce HuIFN-beta or whether the patient's cells produce an antigenically different variant of HuIFN-beta. We demonstrate that a fibroblast cell strain established from this patient produces HuIFN-beta which does not from a serological standpoint react differently from the HuIFN-beta preparation administered. The conclusion is drawn that the antibodies against therapeutic HuIFN-beta are reacting like autoantibodies with the patient's own HuIFN-beta.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6180097     DOI: 10.1089/jir.1982.2.107

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  4 in total

1.  Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A.

Authors:  B Fleischer; S Fleischer; K Maier; K H Wiedmann; M Sacher; H Thaler; A Vallbracht
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

2.  Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.

Authors:  C Ross; M B Hansen; T Schyberg; K Berg
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

3.  Biosynthetic human interferon treatment of herpetic keratitis.

Authors:  G Smolin
Journal:  Trans Am Ophthalmol Soc       Date:  1983

4.  Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection.

Authors:  K Maier; P Gabriel; E Koscielniak; Y D Stierhof; K H Wiedmann; B Flehmig; A Vallbracht
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.